Page last updated: 2024-08-24

motapizone and cardiovascular agents

motapizone has been researched along with cardiovascular agents in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fischer, W; Hanselle, U; Huhmann, W; Schulz, V; Zietsch, V2
Schade, FU; Schudt, C1

Trials

1 trial(s) available for motapizone and cardiovascular agents

ArticleYear
Inhibition of thrombocyte aggregation by oral motapizone and other drugs.
    European journal of clinical pharmacology, 1986, Volume: 31, Issue:4

    Topics: Adult; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Female; Fibrinolytic Agents; Humans; Male; Platelet Aggregation; Pyridazines

1986

Other Studies

2 other study(ies) available for motapizone and cardiovascular agents

ArticleYear
Hypotensive and antiplatelet actions of motapizone depend on dose and time after ingestion.
    European journal of clinical pharmacology, 1986, Volume: 31, Issue:4

    Topics: Adult; Blood Pressure; Cardiovascular Agents; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Heart Rate; Humans; Male; Platelet Aggregation; Pyridazines

1986
The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
    European journal of pharmacology, 1993, Jan-05, Volume: 230, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiovascular Agents; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Epoprostenol; Isoenzymes; Lipopolysaccharides; Macrophages; Male; Mice; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Platelet Aggregation Inhibitors; Pyridazines; Pyrrolidinones; Rolipram; SRS-A; Tumor Necrosis Factor-alpha

1993